Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).

<h4>Objective</h4>To assess patterns of anti-osteoporosis medication (AOM) use over 3 years among women at high risk of major fracture.<h4>Methods</h4>The GLOW registry follows a cohort of more than 40,000 women aged ≥ 55 from 615 primary care practices in 10 countries. Self-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stephen Gehlbach, Frederick H Hooven, Allison Wyman, Adolfo Diez-Perez, Jonathan D Adachi, Xuemei Luo, Andrew G Bushmakin, Frederick A Anderson, GLOW Investigators
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/88c1bae99a174d21a8d7bc6c56271aa7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:88c1bae99a174d21a8d7bc6c56271aa7
record_format dspace
spelling oai:doaj.org-article:88c1bae99a174d21a8d7bc6c56271aa72021-11-18T08:40:58ZPatterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).1932-620310.1371/journal.pone.0082840https://doaj.org/article/88c1bae99a174d21a8d7bc6c56271aa72013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24376589/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>To assess patterns of anti-osteoporosis medication (AOM) use over 3 years among women at high risk of major fracture.<h4>Methods</h4>The GLOW registry follows a cohort of more than 40,000 women aged ≥ 55 from 615 primary care practices in 10 countries. Self-administered surveys (baseline, 12, 24, and 36 months) collected data on patient characteristics, perception of fracture risk, and AOM use. FRAX scores were calculated from the baseline surveys and women classified as high risk if their FRAX 10-year probability of major fracture was ≥ 20%.<h4>Results</h4>A total of 5774 women were classified as at high risk and had complete data over 3 years. At baseline, 2271 (39%) reported receiving AOM, 739 (13%) reported prior but not current use, and 2764 (48%) said they had never used AOM. Over 3 years, 85% of baseline non-users continued as non-users and 15% initiated AOM; among baseline users, 49% continued the same medication class, 29% stopped AOM, and 12% switched. Women who stopped AOM were less likely to self-report osteoporosis (HR 0.56, 95% CI 0.42-0.75) than women who continued AOM. Compared with non-users who did not begin treatment, women initiating AOM were more likely to report a diagnosis of osteoporosis (HR 11.3, 95% CI 8.2-15.5) or osteopenia (HR 4.1, 95% CI 2.9-5.7) and be very concerned about osteoporosis (HR 1.9, 95% CI 1.3-2.8).<h4>Conclusions</h4>Less than 40% of women at high risk of fracture reported taking AOM. Women who stopped AOM were less likely to believe they have osteoporosis. Women who initiated treatment appeared motivated primarily by a diagnosis of osteoporosis or osteopenia and concern about the condition.Stephen GehlbachFrederick H HoovenAllison WymanAdolfo Diez-PerezJonathan D AdachiXuemei LuoAndrew G BushmakinFrederick A AndersonGLOW InvestigatorsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 12, p e82840 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Stephen Gehlbach
Frederick H Hooven
Allison Wyman
Adolfo Diez-Perez
Jonathan D Adachi
Xuemei Luo
Andrew G Bushmakin
Frederick A Anderson
GLOW Investigators
Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
description <h4>Objective</h4>To assess patterns of anti-osteoporosis medication (AOM) use over 3 years among women at high risk of major fracture.<h4>Methods</h4>The GLOW registry follows a cohort of more than 40,000 women aged ≥ 55 from 615 primary care practices in 10 countries. Self-administered surveys (baseline, 12, 24, and 36 months) collected data on patient characteristics, perception of fracture risk, and AOM use. FRAX scores were calculated from the baseline surveys and women classified as high risk if their FRAX 10-year probability of major fracture was ≥ 20%.<h4>Results</h4>A total of 5774 women were classified as at high risk and had complete data over 3 years. At baseline, 2271 (39%) reported receiving AOM, 739 (13%) reported prior but not current use, and 2764 (48%) said they had never used AOM. Over 3 years, 85% of baseline non-users continued as non-users and 15% initiated AOM; among baseline users, 49% continued the same medication class, 29% stopped AOM, and 12% switched. Women who stopped AOM were less likely to self-report osteoporosis (HR 0.56, 95% CI 0.42-0.75) than women who continued AOM. Compared with non-users who did not begin treatment, women initiating AOM were more likely to report a diagnosis of osteoporosis (HR 11.3, 95% CI 8.2-15.5) or osteopenia (HR 4.1, 95% CI 2.9-5.7) and be very concerned about osteoporosis (HR 1.9, 95% CI 1.3-2.8).<h4>Conclusions</h4>Less than 40% of women at high risk of fracture reported taking AOM. Women who stopped AOM were less likely to believe they have osteoporosis. Women who initiated treatment appeared motivated primarily by a diagnosis of osteoporosis or osteopenia and concern about the condition.
format article
author Stephen Gehlbach
Frederick H Hooven
Allison Wyman
Adolfo Diez-Perez
Jonathan D Adachi
Xuemei Luo
Andrew G Bushmakin
Frederick A Anderson
GLOW Investigators
author_facet Stephen Gehlbach
Frederick H Hooven
Allison Wyman
Adolfo Diez-Perez
Jonathan D Adachi
Xuemei Luo
Andrew G Bushmakin
Frederick A Anderson
GLOW Investigators
author_sort Stephen Gehlbach
title Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
title_short Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
title_full Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
title_fullStr Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
title_full_unstemmed Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
title_sort patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the global longitudinal study of osteoporosis in women (glow).
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/88c1bae99a174d21a8d7bc6c56271aa7
work_keys_str_mv AT stephengehlbach patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT frederickhhooven patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT allisonwyman patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT adolfodiezperez patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT jonathandadachi patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT xuemeiluo patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT andrewgbushmakin patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT frederickaanderson patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
AT glowinvestigators patternsofantiosteoporosismedicationuseamongwomenathighriskoffracturefindingsfromthegloballongitudinalstudyofosteoporosisinwomenglow
_version_ 1718421456824565760